19-oxo-delta(4) androstene-3,17-dione is a synthetic steroid hormone that has been shown to have a variety of biological effects.
**Structure and Properties:**
* It is a derivative of testosterone with a ketone group at position 19.
* It is a crystalline solid with a molecular weight of 300.4 g/mol.
* It is poorly soluble in water but soluble in organic solvents.
**Biological Effects:**
19-oxo-delta(4) androstene-3,17-dione has been shown to:
* **Promote muscle growth:** It has anabolic effects, increasing muscle mass and strength.
* **Increase erythropoiesis:** It stimulates the production of red blood cells.
* **Have androgenic effects:** It has effects on male sexual characteristics, such as hair growth and deepening of the voice.
* **Affect lipid metabolism:** It can influence the levels of cholesterol and triglycerides in the blood.
**Importance in Research:**
19-oxo-delta(4) androstene-3,17-dione is of interest to researchers for several reasons:
* **Potential therapeutic uses:** Its anabolic and androgenic properties have led to investigations into its potential use in conditions such as muscle wasting and hypogonadism.
* **Understanding steroid metabolism:** It is a useful tool for studying the metabolism of steroids in the body.
* **Sports doping:** It has been used illicitly as a performance-enhancing drug in sports.
**Safety Concerns:**
Like other anabolic steroids, 19-oxo-delta(4) androstene-3,17-dione can have serious side effects, including:
* **Liver damage**
* **Cardiovascular problems**
* **Mood swings**
* **Acne**
* **Hair loss**
**Research and Regulation:**
Due to its potential for misuse and the associated health risks, 19-oxo-delta(4) androstene-3,17-dione is subject to strict regulations and is not readily available for general use. Research on this compound continues to focus on understanding its biological effects and exploring its potential therapeutic applications while mitigating its potential risks.
19-oxo-delta(4) androstene-3,17-dione: RN given refers to unlabeled parent cpd; an estrogen prodrug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3,17-dioxoandrost-4-en-19-al : An androstanoid that is androst-4-en-19-al substituted by oxo groups at positions 3 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 92854 |
| CHEBI ID | 799 |
| SCHEMBL ID | 874927 |
| MeSH ID | M0062441 |
| Synonym |
|---|
| 3,17-dioxoandrost-4-en-19-al |
| 19-oxo-delta(4) androstene-3,17-dione |
| 19-oxoandrostendione |
| 4-androstene-3,17-dione-19-al |
| 19-oxo-androst-4-ene-3,17-dione |
| 19-aldehydo-4-androstene-3,17-dione |
| 19-keto-delta(4) androstene-3,17-dione |
| CHEBI:799 |
| androst-4-en-19-al,17-dioxo- |
| nsc-76985 |
| 19-aldoandrostenedione |
| 968-49-0 |
| nsc76985 |
| 19-oxoandrost-4-ene-3,17-dione |
| C05297 |
| 19-oxoandrostenedione |
| LMST02020083 |
| (8r,9s,10s,13s,14s)-13-methyl-3,17-dioxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde |
| A845648 |
| (8r,9s,10s,13s,14s)-13-methyl-3,17-dioxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde |
| 19-oxoandro-4-stene-3,17-dione |
| androst-4-en-19-al, 3,17-dioxo- |
| nsc 76985 |
| unii-x07f7694nw |
| x07f7694nw , |
| 4-androsten-19-al-3,17-dione |
| SCHEMBL874927 |
| androstenedione, 19-aldehyde |
| 3,17-dioxoandrost-4en-19-al |
| XRCFMDPVHKVRDJ-BGJMDTOESA-N |
| DTXSID00242509 |
| 4-androsten-3,17-dione 19-aldehyde |
| Q27105362 |
| (3as,3br,9as,9bs,11as)-11a-methyl-1,7-dioxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-9a-carbaldehyde |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 17-oxo steroid | Any oxo steroid carrying the oxo group at position 17. |
| 19-oxo steroid | |
| androstanoid | Any steroid based on an androstane skeleton and its derivatives. |
| steroid aldehyde | Any steroid substituted by a formyl group. |
| 3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| estradiol biosynthesis I | 5 | 9 |
| estradiol biosynthesis I (via estrone) | 2 | 9 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||